CAMP4 Therapeutics Corporation (CAMP)

CAMP4 Therapeutics Corporation at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

CAMP4 Therapeutics Corporation (CAMP) is a Biotechnology company based in US with a market capitalization of $67.8M. Free cash flow was negative at -$29.8M. This page tracks CAMP's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

US · 55 employees · IPO Oct 11, 2024

Valuation

Valuation & price

$4.31as of May 17, 2026· -39.6% vs 52w high

P/E ratio

Latest-FY diluted EPS

1.42

P/B ratio

Market cap ÷ book equity

Dividend yield

Price — last 12 months

$7.13$4.25$1.36Jul 25Jan 26Jul 26
$1.3652-week range$7.13
Loading valuation history…

Fundamentals

Key fundamentals

$67.8M

Market cap

Revenue growth (YoY)

53.1%

Gross margin

-$29.8M

Free cash flow (USD)

-$107.5M

Net debt

Net cash position

55.8%

Share dilution

1/4

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

20172025

$351.1M$3.5M

Free cash flow by year

20172025

$17.8M-$29.8M

Gross margin by year

20212025

39.7%53.1%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

0

Insider sells · 90 days

Earnings

Last report: 10-Q filed May 7, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • 8-K eventJun 12, 2026Filing

    Inducement Plan Established

  • 8-K eventMay 14, 2026Filing

    Preclinical Data Presentation

  • 8-K eventMay 7, 2026Filing

    Earnings Release

  • Quarterly reportMay 7, 2026Filing

    10-Q Filed

Questions

Frequently asked questions

What is CAMP4 Therapeutics Corporation's market cap?

CAMP4 Therapeutics Corporation (CAMP) has a market capitalization of $67.8M.

What is CAMP's P/E ratio?

A meaningful P/E ratio is not available for CAMP — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.

What is CAMP's price-to-book (P/B) ratio?

CAMP trades at 1.42 times book value per share.

Are insiders buying CAMP stock?

SEC Form 4 filings show no open-market insider buys at CAMP4 Therapeutics Corporation in the last 90 days (0 sells).

Same arena

Related companies in Biotechnology

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.